Literature DB >> 18574462

Moving towards better predictors of drug-induced torsades de pointes.

A S Bass1, B Darpo, J-P Valentin, P Sager, K Thomas.   

Abstract

Drug-induced torsades de pointes (TdP) remains a significant public health concern that has challenged scientists who have the responsibility of advancing new medicines through development to the patient, while assuring public safety. As a result, from the point of discovering a new molecule to the time of its registration, significant efforts are made to recognize potential liabilities, including the potential for TdP. With this background, the ILSI (HESI) Proarrhythmia Models Project Committee recognized that there was little practical understanding of the relationship between drug effects on cardiac ventricular repolarization and the rare clinical event of TdP. A workshop was therefore convened at which four topics were considered including: Molecular and Cellular Biology Underlying TdP, Dynamics of Periodicity, Models of TdP Proarrhythmia and Key Considerations for Demonstrating Utility of Pre-Clinical Models. The series of publications in this special edition has established the background, areas of debate and those that deserve scientific pursuit. This is intented to encourage the research community to contribute to these important areas of investigation in advancing the science and our understanding of drug-induced proarrhythmia.

Entities:  

Mesh:

Year:  2008        PMID: 18574462      PMCID: PMC2492097          DOI: 10.1038/bjp.2008.215

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity.

Authors:  Rashmi R Shah
Journal:  Fundam Clin Pharmacol       Date:  2002-04       Impact factor: 2.748

Review 2.  Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.

Authors:  Eric P Brass; Roger J Lewis; Raymond Lipicky; James Murphy; William R Hiatt
Journal:  Clin Pharmacol Ther       Date:  2006-03       Impact factor: 6.875

3.  Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States.

Authors:  Cheryl Enger; Clorinda Cali; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-09       Impact factor: 2.890

4.  Risk of selected serious cardiac events among new users of antihistamines.

Authors:  J A Staffa; J K Jones; C B Gable; J P Verspeelt; W K Amery
Journal:  Clin Ther       Date:  1995 Nov-Dec       Impact factor: 3.393

5.  Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.

Authors:  David A Morrow; Benjamin M Scirica; Ewa Karwatowska-Prokopczuk; Sabina A Murphy; Andrzej Budaj; Sergei Varshavsky; Andrew A Wolff; Allan Skene; Carolyn H McCabe; Eugene Braunwald
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

Review 6.  Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.

Authors:  Jean T Barbey; Ralph Lazzara; Douglas P Zipes
Journal:  J Cardiovasc Pharmacol Ther       Date:  2002-04       Impact factor: 2.457

7.  QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans.

Authors:  Takeshi Omata; Chieko Kasai; Munehiro Hashimoto; Toshiyasu Hombo; Keiji Yamamoto
Journal:  J Pharmacol Sci       Date:  2005       Impact factor: 3.337

Review 8.  Cardiotoxicity of new antihistamines and cisapride.

Authors:  Ilari Paakkari
Journal:  Toxicol Lett       Date:  2002-02-28       Impact factor: 4.372

9.  Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization.

Authors:  J P Hanrahan; P W Choo; W Carlson; D Greineder; G A Faich; R Platt
Journal:  Ann Epidemiol       Date:  1995-05       Impact factor: 3.797

10.  Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability.

Authors:  C M Pratt; S Ruberg; J Morganroth; B McNutt; J Woodward; S Harris; J Ruskin; L Moye
Journal:  Am Heart J       Date:  1996-03       Impact factor: 4.749

View more
  4 in total

Review 1.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

2.  International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.

Authors:  A S Bass; B Darpo; A Breidenbach; K Bruse; H S Feldman; D Garnes; T Hammond; W Haverkamp; C January; J Koerner; C Lawrence; D Leishman; D Roden; J P Valentin; M A Vos; Y-Y Zhou; T Karluss; P Sager
Journal:  Br J Pharmacol       Date:  2008-08       Impact factor: 8.739

Review 3.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 4.  ILSI Health and Environmental Sciences Institute (HESI), global leader in advancing translational science to create science-based solutions for a sustainable, healthier world.

Authors:  Ayako Takei
Journal:  Genes Environ       Date:  2015-06-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.